Biotech RadarJobs updated

COMPANY

SCILEX

scilexholding.com ↗ · West Coast

FDA-cleared device company Clinical Phase 2

Profile checked Oct 10, 2026

Keywords: Moderate to Severe Acute Lower Back Pain Lumbosacral Radicular Pain SP-103 SP-104 SP-102

$387.0MRaised (2 yrs)13Trials (company is sponsor)

Timeline

  1. Raise Private placement: $20M (total, as published), announced Jan 30, 2026. Source: company release on GlobeNewswire. source ↗
  2. Raise Private placement: amount not published, announced Nov 26, 2025. Source: company release on GlobeNewswire. source ↗
  3. Partnership Partnership / licensing announced Nov 4, 2025. Source: SEC filing. source ↗
  4. Raise Private placement: $150M (total, as published), announced Sep 25, 2025. Source: SEC filing. source ↗
  5. Raise Private placement: $200M (total, as published), announced Sep 23, 2025. Source: SEC filing. source ↗
  6. Partnership Partnership / licensing announced Jan 21, 2025. Source: company release on GlobeNewswire. source ↗
  7. Raise Follow-on offering — Registered direct: $17M (total, as published), announced Dec 13, 2024. Source: SEC filing. source ↗
  8. Trial start Phase 2: Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain source ↗
  9. Trial start Phase 1: Pharmacokinetics of SP-104 source ↗
  10. Trial start Phase 1: Study to Evaluate the Safety of SP-104 source ↗
  11. Trial start Phase 1: Clinical Adhesion Study Between ZTlido 1.8% and Three Over-the-counter External Analgesic Lidocaine-containing Patches source ↗
  12. Trial start Phase 1: Pharmacokinetics and Adhesion of Lidocaine Topical System 1.8% With Water Exposure source ↗
  13. Trial start Phase 1: Pharmacokinetic Study of SP-103 in Healthy Adult Human Subjects source ↗
  14. Trial start Phase 1: Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Generic Lidocaine Patch 5% in Healthy, Adult, Human Subjects source ↗
  15. Trial start Phase 3: Corticosteroid Lumbar Epidural Analgesia for Radiculopathy source ↗
  16. Trial start Phase 1: Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Lidocaine Patch 5% and Lidocaine Medicated Plaster 5% in Healthy, Adult, Human Subjects source ↗
  17. Trial start Phase 1: Comparative Pharmacokinetic Study of Lidocaine Patch 1.8% (ZTlido™) and Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects source ↗
  18. Trial start Phase 1: Pharmacokinetics and Adhesion of Lidocaine Topical System 1.8% Under Conditions of Heat and Exercise source ↗
  19. Trial start Phase 1: Adhesion of Lidocaine Topical System 1.8% source ↗
  20. Trial start Phase 1: Pharmacokinetic Study of Lidocaine Patch 1.8% Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects source ↗

Funding

Raised: $387.0M. Last 2 years.

Clinical trials (lead sponsor) 13

RecordTitlePhaseStatusStartPrimary completion
NCT05096494Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back PainPhase 2CompletedApr 29, 2022May 30, 2023 (actual)
NCT04150536Pharmacokinetics and Adhesion of Lidocaine Topical System 1.8% Under Conditions of Heat and ExercisePhase 1CompletedJan 8, 2016Jan 25, 2016 (actual)
NCT04144192Pharmacokinetic Study of Lidocaine Patch 1.8% Lidocaine Patch 5% (Lidoderm®) in Healthy SubjectsPhase 1CompletedApr 28, 2014Jul 24, 2014 (actual)
NCT04319926Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Generic Lidocaine Patch 5% in Healthy, Adult, Human SubjectsPhase 1CompletedSep 7, 2018Sep 9, 2018 (actual)
NCT03372161Corticosteroid Lumbar Epidural Analgesia for RadiculopathyPhase 3CompletedDec 8, 2017Aug 20, 2021 (actual)
NCT05002946Pharmacokinetics of SP-104Phase 1CompletedJan 11, 2022Apr 24, 2022 (actual)
NCT04958876Study to Evaluate the Safety of SP-104Phase 1CompletedOct 4, 2021Dec 20, 2021 (actual)
NCT05106400Clinical Adhesion Study Between ZTlido 1.8% and Three Over-the-counter External Analgesic Lidocaine-containing PatchesPhase 1CompletedJul 1, 2021Jul 21, 2021 (actual)
NCT04819581Pharmacokinetic Study of SP-103 in Healthy Adult Human SubjectsPhase 1CompletedAug 3, 2019Aug 27, 2019 (actual)
NCT04784728Pharmacokinetics and Adhesion of Lidocaine Topical System 1.8% With Water ExposurePhase 1CompletedAug 21, 2019Aug 31, 2019 (actual)
NCT04320173Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Lidocaine Patch 5% and Lidocaine Medicated Plaster 5% in Healthy, Adult, Human SubjectsPhase 1CompletedFeb 14, 2017Mar 22, 2017 (actual)
NCT04312750Adhesion of Lidocaine Topical System 1.8%Phase 1Completed2015-122015-12 (actual)
NCT04149938Comparative Pharmacokinetic Study of Lidocaine Patch 1.8% (ZTlido™) and Lidocaine Patch 5% (Lidoderm®) in Healthy SubjectsPhase 1CompletedSep 28, 2016Oct 27, 2016 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback